Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. (MBRX) will implement a 1-for-20 reverse stock split effective at 12:01 a.m. Eastern Time on October 20, 2026. The company’s common stock will open for trading on The Nasdaq Capital Market that day on a post-split basis under MBRX. Each 20 issued and outstanding shares will become one share, with par value unchanged at $0.001. Outstanding common shares are expected to decline from approximately 20.91 million to approximately 1.05 million, while authorized common shares remain 500 million.
The split will proportionately adjust the share counts and exercise prices for outstanding options and warrants, as well as the share counts for restricted stock unit awards; shares reserved under the equity plan will also be reduced proportionately. No fractional shares will be issued. Instead, holders entitled to a fraction will receive cash based on the fraction multiplied by the average closing sales prices during regular trading hours for the five consecutive trading days immediately preceding the split. Separately, the company says it will require significant additional financing, for which it has no commitments, to conduct its clinical trials.
At Moleculin Biotech, Inc. (MBRX), Chief Science Officer Donald H. Picker received an employment-related grant of 250,000 options to buy common stock on October 15, 2026. The options have an exercise price of $0.3701 per share, and his direct option holdings after the grant were 789,595. Half of the grant vests on the grant date; the other half vests in 18 equal installments over 18 months. The options expire October 15, 2036.
Moleculin Biotech, Inc. CEO and President Walter V. Klemp received grants of 415,000 options and 415,000 restricted stock units on October 15, 2026. The options have a $0.3701 exercise price and expire October 15, 2036; 2,341,335 options were reported following the grant. On the same date, 207,500 restricted stock units converted into common shares, and 48,659 shares were withheld for taxes upon vesting at $0.3701 per share. The awards vest 50% on grant and the remaining 50% in 18 equal installments over 18 months.
Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster received an employment-related grant of 260,000 stock options, exercisable at $0.3701 per share and expiring October 15, 2036, plus 260,000 restricted stock units. On October 15, 2026, 130,000 RSUs converted one-for-one into common stock, and 30,485 shares were withheld for taxes upon vesting at $0.3701 per share. The options and RSUs vest 50% on grant and 50% in 18 equal installments over 18 months.
Moleculin Biotech, Inc. (MBRX) is using an attached presentation for its corporate presentation posted on the company website. The company states that the presentation is furnished, not filed under the Exchange Act, and will not be incorporated by reference into other filings unless specifically identified as incorporated.
Moleculin Biotech, Inc. (MBRX) stockholders approved an increase of 3,861,894 shares in the 2024 Stock Plan, bringing the number of shares authorized for issuance under the plan to 3,875,999, including the increase. Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak were elected as directors. Stockholders also ratified Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved a non-binding advisory resolution on executive compensation.
Stockholders approved board authority to effect a reverse stock split at a ratio from 1-for-2 to 1-for-20, as determined by the board in its sole discretion prior to the one-year anniversary of the Annual Meeting. The proposed amendment to eliminate supermajority voting requirements was not approved; the amendment required affirmative votes from two-thirds of outstanding common shares. As of August 19, 2026, 19,477,380 common shares were outstanding and entitled to vote, and 8,247,089 shares were present or represented, constituting a quorum.
Moleculin Biotech, Inc. is using an attached presentation for its corporate presentation posted on its website. The presentation is furnished, not filed under the Exchange Act, and is not incorporated by reference into other filings unless specifically identified as incorporated.
Moleculin Biotech, Inc. (MBRX) closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for adults with relapsed or refractory acute myeloid leukemia, with 89 subjects enrolled. The company says it remains on track for a comprehensive Part A data readout in the first quarter of 2027.
Part A is randomized and double-blind, comparing two Annamycin doses plus cytarabine with cytarabine plus placebo; outcomes for all arms are measured after one cycle. The planned analysis is expected to assess efficacy and safety across the randomized population and support selection of a dose for Part B. Moleculin said blinded data continue to show a lack of cardiotoxicity. It also disclosed that trial milestones assume timely access to significant additional financing, for which it has no commitments.
Moleculin Biotech, Inc. (MBRX) announced publication of a peer-reviewed pooled analysis of Annamycin’s cardiac safety across five clinical trials. The analysis covered 90 patients with acute myeloid leukemia or metastatic soft tissue sarcoma; paired echocardiographic data were available for 78 patients. Moleculin said an independent evaluation by a Cleveland Clinic cardio-oncology laboratory found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
The authors concluded that the findings support continued clinical evaluation. Annamycin is being evaluated in Moleculin’s MIRACLE program for relapsed or refractory AML. Moleculin said it requires significant additional financing, for which it has no commitments, to conduct the described clinical trials. The company also said the dataset is subject to review of data from future subjects in current and future trials and long-term follow-up with subjects in current trials.
Moleculin Biotech, Inc. (MBRX) announced preclinical data indicating that its lead drug candidate Annamycin (naxtarubicin) has antitumor activity in pancreatic cancer that is partially mediated by CD8+ T-cell cytotoxicity. The findings are being presented at the AACR Conference on Pancreatic Cancer in San Diego, September 25–28, 2026. The results suggest a possible immune-mediated mechanism alongside Annamycin’s direct cytotoxic activity.
The findings come from preclinical models, may not predict results in humans, and Annamycin is not currently in clinical development for pancreatic cancer. Moleculin said its lead clinical program remains the MIRACLE trial evaluating AnnAraC for relapsed or refractory acute myeloid leukemia; the pancreatic cancer findings are separate from that trial. The company stated that it will require significant additional financing, for which it has no commitments, to conduct the clinical trials described, and that its milestones assume timely financing.